{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chi KN"],"funding":["Medical Research Council","National Institute for Health Research (NIHR)","AstraZeneca","Merck Sharp and Dohme"],"pagination":["81-91"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9811161"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(1)"],"pubmed_abstract":["Purpose
Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedure. Optimization of screening techniques may reduce failure rates; however, a need remains for additional testing methods to detect cancers with alterations in homologous recombination repair genes. We evaluated the utility of plasma-derived circulating tumor DNA (ctDNA) in identifying deleterious BRCA1, BRCA2 (BRCA), and ATM alterations in screened patients with mCRPC from the phase III PROfound study.Patients and methods
Tumor tissue samples were sequenced prospectively at Foundation Medicine, Inc. (FMI) using an investigational next-gene"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound."],"pmcid":["PMC9811161"],"funding_grant_id":["NF-SI-0617-10099","MR/W018217/1"],"pubmed_authors":["Chi KN","Corcoran C","Agarwal N","Barrett JC","Qiu P","Barnicle A","Adelman CA","Mateo J","Oxnard GR","Thiery-Vuillemin A","Lai Z","Azad A","Olmos D","Easter A","Dearden S","Sibilla C","Harrington EA","de Bono J"],"additional_accession":[]},"is_claimable":false,"name":"Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.","description":"Purpose
Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedure. Optimization of screening techniques may reduce failure rates; however, a need remains for additional testing methods to detect cancers with alterations in homologous recombination repair genes. We evaluated the utility of plasma-derived circulating tumor DNA (ctDNA) in identifying deleterious BRCA1, BRCA2 (BRCA), and ATM alterations in screened patients with mCRPC from the phase III PROfound study.Patients and methods
Tumor tissue samples were sequenced prospectively at Foundation Medicine, Inc. (FMI) using an investigational next-gene","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-05-10T06:55:14.424Z","creation":"2025-04-07T03:20:10.682Z"},"accession":"S-EPMC9811161","cross_references":{"pubmed":["36043882"],"doi":["10.1158/1078-0432.CCR-22-0931"]}}